Acute lymphoblastic leukemia is clinically cured when chemotherapy is stopped for five years or when disease-free survival is achieved for ten years. Acute lymphoblastic leukemia is a heterogeneous disease in terms of pathology and incidence groups, and can develop in different age groups. It occurs most often in children and adolescents and often presents with clinical manifestations such as fever, anemia, bleeding and bone pain, often accompanied by enlarged lymph nodes and to a lesser extent mild to moderate liver and spleen enlargement. Acute lymphoblastic leukemia in children has clear biological and clinical prognostic features and a high long-term survival rate. Adult acute lymphoblastic leukemia is poorly tolerated by intense chemotherapy because of its different disease biology. Although the initial treatment induces a high remission rate, most patients will eventually relapse, with a lower long-term survival rate and an unsatisfactory response to treatment. Patients with acute lymphoblastic leukemia are usually considered clinically cured of acute lymphoblastic leukemia if they have not relapsed after five years of cessation of chemotherapy or ten years of disease-free survival. However, relapse may occur again, and patients are advised to go to the hospital for regular review. If the diagnosis of acute lymphoblastic leukemia is confirmed, it is recommended to consult a medical professional and undergo standardized treatment as soon as possible in order to minimize the adverse effects of the disease.